ELISA/assay

Human Mu type opioid receptor (OPRM1) ELISA Kit

MBS7225318

48-Strip-Wells

470 USD

ELISA Kit

Human Mu type opioid receptor (OPRM1) ELISA Kit

Mu type opioid receptor (OPRM1)

Mu-type opioid receptor; Mu-type opioid receptor; mu-type opioid receptor; mu opiate receptor; mu opioid receptor hMOR-1a; opioid receptor, mu 1; Mu opiate receptor; Mu opioid receptor; MOP; hMOP

OPRM1

OPRM1; OPRM1; MOP; MOR; LMOR; MOR1; OPRM; M-OR-1; MOR1; M-OR-1; MOR-1; MOP; hMOP

OPRM_HUMAN

Human

This assay has high sensitivity and excellent specificity for detection of OPRM-1. No significant cross-reactivity or interference between OPRM-1 and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between OPRM-1 and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

Intended Uses: This OPRM-1 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human OPRM-1. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Neuroscience

Principle of the assay: OPRM-1 ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-OPRM-1 antibody and an OPRM-1-HRP conjugate. The assay sample and buffer are incubated together with OPRM-1-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the OPRM-1 concentration since OPRM-1 from samples and OPRM-1-HRP conjugate compete for the anti-OPRM-1 antibody binding site. Since the number of sites is limited, as more sites are occupied by OPRM-1 from the sample, fewer sites are left to bind OPRM-1-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The OPRM-1 concentration in each sample is interpolated from this standard curve.

2851402

P35372.2

20,188 Da

Class A/1 (Rhodopsin-like Receptors) Pathway (106357); Estrogen Signaling Pathway (799177); Estrogen Signaling Pathway (799197); G Alpha (i) Signalling Events Pathway (119550); G-protein Activation Pathway (106494); GPCR Downstream Signaling Pathway (119548); GPCR Ligand Binding Pathway (161020); GPCRs, Class A Rhodopsin-like Pathway (198886); IL4-mediated Signaling Events Pathway (137933); Morphine Addiction Pathway (552665)

This gene encodes one of at least three opioid receptors in humans; the mu opioid receptor (MOR). The MOR is the principal target of endogenous opioid peptides and opioid analgesic agents such as beta-endorphin and enkephalins. The MOR also has an important role in dependence to other drugs of abuse, such as nicotine, cocaine, and alcohol via its modulation of the dopamine system. The NM_001008503.2:c.118A G allele has been associated with opioid and alcohol addiction and variations in pain sensitivity but evidence for it having a causal role is conflicting. Multiple transcript variants encoding different isoforms have been found for this gene. Though the canonical MOR belongs to the superfamily of 7-transmembrane-spanning G-protein-coupled receptors some isoforms of this gene have only 6 transmembrane domains. [provided by RefSeq, Oct 2013]

MOR-1: a Gi-protein-coupled receptor for beta-endorphin, morphine and other opiates. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Ligand-binding inactivates adenylyl cyclase, and activates a variety of G-beta-gamma-dependent pathways including the MAPK and the PI3K/Akt cascades. Two splice-variant isoforms have been described. Protein type: GPCR, family 1; Membrane protein, multi-pass; Receptor, GPCR; Membrane protein, integral. Chromosomal Location of Human Ortholog: 6q24-q25. Cellular Component: dendrite cytoplasm; Golgi apparatus; neuron projection; focal adhesion; endoplasmic reticulum; integral to plasma membrane; plasma membrane; perikaryon; sarcolemma; lipid raft. Molecular Function: G-protein coupled receptor activity; voltage-gated calcium channel activity; neuropeptide binding; protein domain specific binding; protein binding; G-protein alpha-subunit binding; G-protein beta-subunit binding; filamin binding; beta-endorphin receptor activity. Biological Process: response to food; positive regulation of neurogenesis; positive regulation of nitric oxide biosynthetic process; wound healing; negative regulation of nitric oxide biosynthetic process; cellular response to stress; negative regulation of adenylate cyclase activity; locomotory behavior; response to lipopolysaccharide; behavioral response to ethanol; sensory perception of pain; response to cocaine; G-protein signaling, coupled to cyclic nucleotide second messenger; negative regulation of cell proliferation; synaptic transmission; elevation of cytosolic calcium ion concentration; neuropeptide signaling pathway; reduction of cytosolic calcium ion concentration; positive regulation of appetite; sensory perception; opioid receptor, adenylate cyclase inhibiting pathway; G-protein signaling, coupled to IP3 second messenger (phospholipase C activating); regulation of sensory perception of pain; regulation of excitatory postsynaptic membrane potential; dopamine receptor, adenylate cyclase activating pathway; acute inflammatory response to antigenic stimulus. Disease: Epilepsy, Idiopathic Generalized

48-Strip-Wells

470 USD

96-Strip-Wells

675